By MountainSageNaturalHealth.com Editorial Team
Direct Answer and Scope
“Kratom alkaloids” most often refers to two compounds: mitragynine, the primary active alkaloid naturally present in kratom leaf, and 7-hydroxymitragynine (7-OH), a related compound that forms from mitragynine during metabolism or processing. They are chemically related but not the same thing, and federal regulators currently treat them very differently. This page explains what each one is and how it behaves at the receptor level — it does not cover dosing, extraction, or product comparisons, and it does not claim either compound is proven safe or effective for any condition.
What Is Mitragynine
Mitragynine is the most well-studied alkaloid found in the leaves of Mitragyna speciosa, the Southeast Asian tree kratom comes from. According to the National Institute on Drug Abuse (NIDA), mitragynine partially activates mu-opioid receptors — the same receptor type opioid medications act on — while also interacting with adrenergic, serotonin, and dopamine receptors.
That spread across multiple receptor types is part of why kratom’s reported effects vary so widely from person to person. NIDA notes that researchers have not established that stimulant-like versus sedative-like effects depend predictably on dose or method of use, despite that being a common claim in kratom marketing.
What Is 7-Hydroxymitragynine (7-OH)
7-OH is not a separate ingredient added to kratom — it’s what mitragynine becomes. NIDA describes 7-OH as a compound that mitragynine breaks down into after it is ingested and metabolized in the body. 7-OH can also form during the drying and processing of the leaf itself, which is why some commercial products are sold with concentrated or isolated 7-OH content rather than relying on the conversion that happens naturally after ingestion.
This distinction is the center of current U.S. regulatory activity. The FDA has stated that its push to restrict 7-OH is aimed at concentrated, isolated 7-OH products — not natural kratom leaf — and the agency has recommended 7-OH be considered for control as a scheduled substance because of its opioid-receptor activity. The FDA has also issued warning letters to companies selling 7-OH-infused drinks, gummies, and powders.
Is Receptor Activity Proof of Benefit
No. Binding to or activating a receptor describes a chemical interaction — it is not, by itself, evidence that a substance is safe, effective, or beneficial for any condition. NIDA states directly that neither kratom nor its related compounds have been proven safe or effective for any medical purpose, and that there are no FDA-approved uses for kratom.
Much of what’s known about mitragynine and 7-OH at the receptor level comes from animal and laboratory studies rather than controlled human clinical trials. That kind of research can identify a compound worth studying further in people; it is a different, earlier type of evidence than a clinical trial result, and the two should not be read as equivalent.
What the Evidence Cannot Tell Us
- Long-term effects are not well understood. NIDA notes that kratom research is relatively new compared to research on more widely used substances, and that case reports — not controlled long-term studies — are the main source of information on extended regular use.
- Product variability complicates everything. Kratom products differ in potency, formulation, and contamination risk, and some have been found to contain heavy metals or harmful bacteria unrelated to the plant itself.
- Addiction and withdrawal risk is still being characterized. Kratom use does not have a specific diagnosis in the DSM-5, but researchers have observed mild-to-moderate withdrawal symptoms in some regular users. Both mitragynine and 7-OH act on receptors associated with addictive potential, though animal studies suggest their addictive potential may differ from one another.
- 7-OH’s respiratory risk profile differs from mitragynine’s. In laboratory models, 7-OH has been shown to cause respiratory depression that can be reversed with naloxone, while mitragynine itself does not appear to produce the same effect at the rate the body converts it to 7-OH.
None of this is a judgment about any individual product. It reflects where federal research agencies say the evidence currently stands, as of their most recent published updates.
Appropriate Next Step
If you’re trying to understand a specific product label — strain name, alkaloid content claims, or 7-OH disclosures — the most reliable path is reading primary regulatory sources directly, since this is an area where federal guidance is actively evolving. The FDA’s 7-OH product page and NIDA’s kratom research topic page are both maintained and updated as new findings and enforcement actions occur.
If you’re weighing kratom use for a specific health reason, that’s a conversation for a licensed healthcare provider who knows your medication list and health history, particularly given the documented drug-interaction and polysubstance-use risks in the research. For general product-category background, our Golden Monk kratom review covers how strain marketing and label transparency vary across vendors — note that piece is a commercial product review, not a clinical resource.